Daniel K. Inouye College of Pharmacy

Permanent URI for this community

https://hdl.handle.net/10790/2801

Browse

Now showing 1 - 19 of 19

Comparative effectiveness of the A.L.O.H.A. project didactic training versus the integrated mixture of the didactic and experiential training programs on knowledge, confidence, and empathy of students enrolled in doctor of pharmacy program.
(2017-04-06) Jose, Abraham C.; Mizusawa, Kelsea A.; Mow, Lauryn P.; Gomez, Lara; Wongwiwatthananukit, Supakit
Effective pharmaceutical care includes components of knowledge, skills, confidence, and empathy, which are utilized throughout the wellness screening and consultation process. The organization puts its members through training that focuses on proper screening techniques, knowledge of common disease states, and development of effective communication through counseling with patients. Our mission fits into the CAPE Educational Outcomes in promoting health improvement, wellness, and disease prevention for individuals and communities (promoter) and educating patients and communities (educator).
Medicare Part D prescribing changes of tricyclic antidepressants between 2013 and 2014
(2017-04-11) So, Nadine W.; Taira, Deborah
Tricyclic antidepressants were the primary pharmacologic treatment for depression in the United States from the 1960s to the late 1980s. Since then, other classes of antidepressants, such as Selective Serotonin Reuptake Inhibitors, have replaced its use as first-line agents due to their more favorable side-effect profile and proven equal efficacy. Tricyclic antidepressants are included in the Beers Criteria because of their potentially harmful side effects in the elderly (e.g. cognitive impairment, delirium, sedation, and orthostatic hypotension). The purpose of this study is to evaluate the changes in prescribing of tricyclic antidepressants from 2013 to 2014 in Medicare beneficiaries.
Evaluation of antioxidant and anti-cancer activities of Fucose-containing sulfated polysaccharide (FCSPs) from Hawaiian Marine Algae
(2018-04-03) Fukuchi, Ashley; Sang-ngern, Mayuramas; Sunada, Nathan; Phosri, Santi; Tan, Ghee Teng; Chang, Leng Chee
Fucoidan is a group of sulfated polysaccharides isolated from marine algae. Fucoidan exhibits a variety of biological activities which are related to their chemically distinct sulfated fucose backbone. The structures of select fucoidans vary by species, and the structure and bioactivity remains unclear. The fucoidan of Padina sp., Asparagopsis taxiformus, and Nishime Kombu were extracted using four different methods using water at different temperatures. Method 2 gave the highest yield of fucoidan by 1H NMR analysis, whereas method 4 yielded FCSPs with anti-cancer activities. The crude fucoidan of Padina sp. was further purified using ion-exchange chromatography, resulting in the highest yield of fucoidan at 2.5 M NaCl. Cell viability was determined using sulforhodamine B (SRB) assay in five cancer cells (LNCap, PC-3, MCF-7, Caco-2, and LU-1). Both standard and Kombu-extracted fucoidan showed no effects on prostate (LNCaP and PC-3), and breast (MCF-7) cancer cells, but inhibited the growth of colon (Caco-2) and lung (LU-1) cancer cells by 43-74% at concentrations in the range of 50-400 µg/mL. These crude FCSPs also exhibited antioxidant activity. The FRAP values of Nishime Kombu, U-Fn, and Fucoidan Force, were 586.44 ± 107 µM/mg extract, 2922.38 ± 981 µM/mg, and 4212.03 ± 745 µM/mg, respectively.
Development of a "N-Quest" (Naloxone reQuest) mobile application to prevent opioid-related overdose deaths
(2018-04-06) Nguyen, Lena; Nguyen-Huu, Phuong An; Olaguer, Megan; Phan, Joann; Truong, Quan; Wongwiwatthananukit, Supakit; Wongwiwatthananukit, Supakit
Opioid abuse in the United States has increased significantly each year and has contributed to over half a million deaths from 2000 to 2015, prompting the need for better patient education and easier access to naloxone. Currently, the opioid antagonist is available over the counter in various pharmacies and facilities across the nation. However, opioid overdose accidents can occur if the naloxone is not delivered in a timely manner.
Incremental Cost of Cardiovascular Disease, Hypertension and Pain for patients with Diabetes Mellitus
(2018-04-06) Taira, Deborah A.; Mannem, Santhosh; Sumida, Wesley; Davis, James; Shohet, Ralph; Seto, Todd B.
Cost of diabetes in United States(US) was $245b in 2012, much of which resulted from adverse cardiovascular events. The added cost of pain is unknown. The purpose of this study is to examine the incremental cost of comorbid cardiovascular disease, hypertension, and pain for patients with diabetes mellitus.
Opioid Utilization and Cost among elderly and non-elderly Medicare beneficiaries in the United States: A State-level Comparison
(2018-04-06) Taira, Deborah A.; Wu, Kimberly; Sumida, Wesley K.; Taira, Deborah A.; Sumida, Wesley K.
Objective compares opioid utilization and cost among elderly and non-elderly Medicare beneficiaries by state. And examines how percent of opioids used by a provider relates to provider and beneficiary
Beyond Triptans: A Review of New Migraine Medications in Clinical Trials
(2018-04-06) Nakagawa, Christopher; Hino Jr., Garret; Tokumaru, Sheri; Young, Nicole; Tokumaru, Sheri; Young, Nicole
Migraines are a very common and debilitating headache disorder characterized by moderate to severe throbbing headache pain, which can be associated with nausea, vomiting, sensitivity to light and sensitivity to sound.This study is a literature review of recent and ongoing clinical trials for new classes of pharmacologic treatments for acute migraine.
Cost-Effectiveness of Phenytoin and Levetiracetam for Seizure Prophylaxis in Traumatic Brain Injury
(2018-04-06) Young, Nicole; Tokumaru, Sheri; Taira, Deborah; Izumi, Kara; Stern, Tracy; Dittrich, Denise; Asai, Susan; Nakagawa, Kazuma; Tokumaru, Sheri; Taira, Deborah
Seizures are a potential complication associated with traumatic brain injury (TBI), which can lead to secondary brain injury and increased risk for developing post-traumatic epilepsy. Current guidelines recommend the use of antiepileptic drug (AED) for early seizure prophylaxis in patients with TBI. Both phenytoin (PHE) and levetiracetam (LEV) have become standard of practice for seizure prophylaxis in TBI, yet the cost effectiveness is not well studied.
Implementation of a Health Screening Training Process for Second and Third Year Pharmacy Students
(2018-04-10) Paulachak, Kara; Chavez, Rene; Kim, Michelle; Prudencio, Jarred; Kim, Michelle; Prudencio, Jarred
Student pharmacists at the Daniel K. Inouye College of Pharmacy (DKICP) at the University of Hawaii at Hilo frequently participate in community health screening events led by various student organizations. The objective of this study was to evaluate student retention of knowledge of counseling points regarding common community disease states after a standardized health screening training process, measured by a change in scores of a multiple-choice assessment. This study was to assess how effective this training was based on student knowledge retained over the course of the academic year.
Evaluation of Patients Knowledge of Medicare Part D Plan Annual Assessment in a Family Medicine Clinic
(2018-04-10) Hino, Garret; Prudencio, Jarred; Prudencio, Jarred
The Hawaii Island Family Health Center (HIFHC) is a family medicine clinic affiliated with Hilo Medical Center. HIFHC serves as a primary care training program site for medical residents, pharmacy students, nursing students and psychology fellows. Pharmacy services at HIFHC focus on comprehensive medication management, chronic disease state management, drug information consults,and medication access assistance. The objective was designed to assess patient's knowledge regarding open enrollment and their ability to annually reassess Medicare Part D to determine if appointments with a clinical pharmacist should be offered during open enrollment.
Innovative hyperlidipemia screening protocol focusing on 10-year risk of atherosclerotic cardiovascular disease
(2018-04-10) Nakagawa, Christopher; Rhee, Caroline J.; Tran, Vivian L.; Prudencio, Jarred B.; Prudencio, Jarred
Daniel K. Inouye College of Pharmacy's previous hyperlipidemia screening protocol focused on a patient's specific total cholesterol. The objective was to create a screening protocol that incorporates the patient's 10 year atherosclerotic cardiovascular disease (ASCVD) risk score to reflect the 2013 American College of Cardiology (ACC)/American Hear Association (AHA) cholesterol guideline.
Impact of International Pharmaceutical Students' Federation (IPSF) Campaigns on Student Pharmacist Knowledge
(2018-04-10) Huynh, Trish; Tsoi, Nicholas; Chen, Matt; Wong, Veronica; Prudencio, Jarred; Prudencio, Jarred
International Pharmaceutical Students' Federation (IPSF) recommends using various disease-focused community health campaigns to promote public health activities. Student pharmacists from the Daniel K. Inouye College of Pharmacy (DKICP) at the University of Hawaii at Hilo developed a series of lectures based on a number of IPSF campaigns to present to the collegiate body. The purpose of this project is to assess the impact of these public health seminars on student pharmacist knowledge of global healthcare issues.
Access to Medications for Medicare Enrollees Related to Race/Ethnicity: Results from the 2013 Medicare Current Beneficiary Survey
(2018-04-11) Taira, Deborah A.; Shen, Chengli; King, Marshaleen; Landsittel, Doug; Mays, Mary Helen; Sentell, Tetine; Southerland, Janet
Millions of people take prescription medication to manage chronic conditions and treat acute conditions. Using the 2013 Medicare Current Beneficiary Survey, this study examined access to medications related to race/ethnicity, comparing non-Hispanic blacks and Hispanics to whites.
Documenting Social and Behavioral Factors: Insights from Potentially Preventable Hospitalizations
(2018-04-11) Sentell, Tetine L.; Seto, Todd B.; Trinacty, Connie Mah; Braun, Kathryn L.; Quensell, Michelle; Taira, Deborah T.
Potentially preventable hospitalizations are those that could be avoided with access to high quality primary care. This mixed-methods study was performed to understand patient perspectives of factors that lead to their potentially preventable hospitalizations related to diabetes and heart disease.
Informational Briefs from the 6th International Workshop on Rat Lungworm Parasites and Diseases
(2021) Jarvi, Sue; Howe, Kay
This publication came about as a result of research presented at the 6th International Workshop on Angiostrongylus and Angiostrogyliasis (colloquially known as rat lungworm disease) held in Hilo, HI, in January of 2020. We have published the scientific details of many of these studies in a Special Issue of Parasitology (Feb 2021) Vol. 148 (Coordinating Editor JT Ellis, Guest Editor SI Jarvi).
Assessment of Pharmacy Student Knowledge Before and After a Three Hour Medicare Training Session
(2024-11-22) Rosalind Wong, Anuhea Sonnenberg, Michelle Kim, Jarred Prudencio
Title: Assessment of Pharmacy Student Knowledge Before and After a Three-Hour Medicare Training Session Primary Author: Rosalind Wong, P3 Co-Authors: Anuhea Sonnenberg, P2; Michelle Kim, PharmD.; Jarred Prudencio, PharmD., BCACP, BC-ADM Data/Results: Data was collected from a total of 34 DKICP students ranging from first-year to third-years. Participants consisted of eighteen first-year, ten second-year, and four third-year students. The mean total score of pre-questionnaires among all participants was reported as 6.4 compared to post-questionnaires reported as 7.8, with an average increase of 1.4. Comparison between pre- and post-questionnaires provided a two-tailed p-value of 0.0006, with an increase in scores between pre- and post-questionnaires observed between all years. Third-year students had the highest overall average pre- and post-questionnaire scores. First-year students had the largest improvement after the training session, with an average increase of 1.5 points (p-value < 0.0164). Students with previous pharmacy experience scored significantly higher in both pre- and post-questionnaires when compared to those with no experience. Students with no experience had a mean improvement of 2.2 points in their post-questionnaire scores (p-value < 0.0026). Percentage correct increased on all questions when preand post-questionnaires were compared with a mean increase of 12.6% (p-value < 0.0004) on each question after the training sessions were concluded. Conclusion: Overall, there was an increase in post-questionnaire scores in all categories, each showing statistical significance. This demonstrates the positive impact the Medicare training session had on pharmacy students regardless of grade level or prior pharmacy experience and has the potential to increase students’ willingness to engage eligible patients in conversations about Medicare insurance coverage. In the future, other pharmacy schools may consider partnering with their State Health Insurance Assistance Program to deliver a similar service to benefit both pharmacy students and Medicare beneficiaries, proving to be an additional strategy to improve student education and patient care
Analyzing US FDA-Approved Infectious Disease Drugs from 2015-2023
(2024-11-22) Rizamari May Pascua, Tracy Pham, Dianqing Sun
Primary Author: Rizamari May Pascua Co-Authors: Tracy Pham, Dianqing Sun, PhD Presentation Title: Analyzing US FDA-Approved Infectious Disease Drugs from 2015-2023 Purpose: In 2019, there are approximately 10.2 million hospital visits for infectious and parasitic diseases in the US. Because of emerging multi-drug resistance and public health threats, new drugs are urgently needed to combat problematic bacterial, viral, fungal, and parasitic infections. The US Food and Drug Administration (FDA) approved drugs play a crucial role in enhancing optimal patient care, improving clinical outcome, and broadening treatment options. The objective of this study is to review all US FDA approved infectious disease (ID) agents from 2015-2023 and analyze their medicinal chemistry properties, mechanism of action, pharmacokinetic (PK) profiles, and clinical applications. Methods: This study utilized prescribing information and online open resources provided by the US FDA’s Center for Drug Evaluation and Research (CDER). Drug information resources such as Lexicomp and Sanford guide were searched for the dosing, route of administration, PK parameters, and indication of the infectious disease medications. Physicochemical properties and Lipinski’s Rule of 5 such as molecular weight, hydrogen bond donor, hydrogen bond acceptor, logP were obtained from ChemSpider & Scifinder databases and subsequently analyzed to evaluate the oral bioavailability of these infectious disease drugs and rationalize their routes of administration and clinical applications. Results: Based on the data collected from 2015-2023, the US FDA has approved a total of 49 novel infectious disease agents including antiviral, antibacterial, antifungal, and antiparasitic. Specifically, 21 antiviral agents were approved to address a wide spectrum of viral conditions, including 7 for human immunodeficiency virus (HIV), 6 for hepatitis C virus (HCV), 2 for SARS-CoV-2, 2 for ebola virus, 1 for respiratory syncytial virus (RSV), 1 for influenza virus, 1 for cytomegalovirus (CMV), and 1 for smallpox virus. Additionally, 18 new antibacterial agents approved include 2 new chemotypes (cephalosporin-siderophore conjugate antibiotic and anti-tuberculosis agent nitroimidazooxazine), 1 nitroimidazole, 2 fluoroquinolones, 1 rifamycin, 3 tetracyclines, 1 pleuromutilin, 1 aminoglycoside, 5 combination therapy (e.g., beta-lactam/beta-lactamase inhibitor), along with 2 biologic monoclonal antibodies (mAbs). Furthermore, 6 antiparasitic agents and 4 antifungal agents have also been approved since 2015. Notably, several of these agents have been subsequently discontinued from the US market due to commercial and/or practice change reasons. Each of these agents will be comprehensively discussed including chemical class, physicochemical property, mechanism of action, route of administration, and dosing regimen. Further, detailed insights into their PK profiles (e.g., Tmax, half-life, bioavailability, protein binding, metabolism, and excretion) will also be presented. Conclusion: Given rising (multi)drug-resistant microorganisms and evolving public health threats, there is an urgent, unmet clinical need for developing new infectious disease drugs with novel mechanism of action. Since 2015, significant new medicine advances have been made in this field, leading to the US FDA approval of 49 new chemical entity ID drugs. Thus, it is imperative for pharmacists, as drug and pharmacotherapy experts, along with other healthcare professionals, to stay updated regarding these new medication therapies, evaluate these expanded treatment options and provide optimal patient care.
Comparison of Weight Loss Diabetic Medication and Self-reported Obesity Prevalence Rates in the United States in 2021
(2024-11-22) Neilsen Gazo, Bryce Fukunaga
Poster Title: Comparison of weight loss diabetic medication prescribing and self-reported obesity prevalence rates in the United States in 2021 Authors: Neilsen Gazo, P3 Student Pharmacist; Bryce Fukunaga, PharmD Purpose - According to the ADA 2023 guidelines, glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) are effective medications for weight loss in individuals with diabetes. Given the substantial health risks, a focus on weight management is vital. The purpose of this study is to determine if there is an association between the prescribing rates of weight loss diabetic medications, GLP1RA and SGLT2i, and obesity prevalence rates in the United States. Methods - This was a retrospective data analysis, utilizing state prescription information from the 2021 Medicare Provider Utilization and Payment: Part D Prescriber Data. Data on claims and beneficiaries of weight loss diabetic medications across all 50 states available in 2021 were collected, including GLP1RA (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide) and SGLT2i (Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin). Prescribing rates for GLP1RA and SGLT2i, both individually and together, were analyzed. Combination medications containing these agents were excluded. Information on the prevalence of self-reported obesity among adults in the United States for 2021 was gathered from the Centers for Disease Control and Prevention Behavioral Risk Factor Surveillance System (CDC BRFSS). Graphs and heat maps were generated using Microsoft Excel for visual representations. Results - In 2021, the top five states with the highest GLP1RA prescribing rates were Alaska, North Dakota, Massachusetts, North Carolina, and New York. The top five states with the highest SGLT2i prescribing rates were Hawaii, New York, Pennsylvania, Connecticut, and Kentucky. The top five states with the highest GLP1RA plus SGLT2i prescribing rates were New York, Alaska, Hawaii, Pennsylvania, and North Carolina. The top ten states with the highest self-reported obesity prevalence rates were West Virginia, Kentucky, Alabama, Oklahoma, Mississippi, Arkansas, Louisiana, South Dakota, Ohio, and Missouri. Kentucky had one of the highest SGLT2i prescribing rates and was also within the top ten states with the highest self-reported obesity prevalence rates. All other states mentioned in the top five states for GLP1RA, SGLT2i, and GLP1RA plus SGLT2i prescribing rates were not among the top ten states with the highest self-reported obesity prevalence rates. Conclusion - There was no strong correlation between the prescribing rates of GLP1RA and SGLT2i and obesity prevalence rates in the United States in 2021. Some limitations of this study include limited age group populations of Medicare Part D data and the subjectiveness of self-reported obesity prevalence. Further research is warranted to observe larger sample sizes with greater ranges of age groups to further evaluate the correlation of this study
Examining US FDA Approved Central Nervous Drugs from 2015-2023
(2024-11-22) Vincent Tran, Cierra Fujimoto, Dianqing Sun
Title: Examining US FDA Approved Central Nervous System Drugs from 2015-2023 Vincent Tran, Cierra Fujimoto, Dianqing Sun Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, Hawaii 96720, United States Purpose: Since 2015, the US Food and Drug Administration (FDA) has approved 400 new chemical entity and biologic drugs with approximately 11 percent of these drugs falling within the central nervous system (CNS) category. CNS drugs mediate the functioning of the brain and spinal cord, and also regulate the human body’s physical and mental well-being. The purpose of this study is to conduct a comprehensive analysis and overview of the medicinal and physicochemical properties, pharmacokinetic (PK) profiles, and clinical applications of these FDA approved CNS drugs from 2015-2023. Methods: This data analysis was conducted using new molecular entity and new therapeutic biological product approval online resources provided by the US FDA’s Center for Drug Evaluation and Research (CDER). Literature review was performed by searching online databases such as Lexicomp and prescribing information document. Physicochemical properties were obtained from ChemSpider and Chemfinder database. Lipinski’s Rule of Five (molecular weight, hydrogen bond acceptor, hydrogen bond donor, and LogP) was used to assess the oral bioavailability, routes of administration, and rationalize their clinical applications of these CNS agents. Results: As of September 2023, the US FDA has approved 400 new chemical entity and therapeutic biologic drugs since 2015 with a total of 44 new CNS drug approvals. Among the CNS drug classes, the highest number of new CNS drugs approvals was for mental disorders (22.7%), followed by migraines (20.5%), anti-seizure (11.4%), sleeping disorders (9.1%), amyotrophic lateral sclerosis (ALS) (6.8%), multiple sclerosis (6.8%), Parkinson’s disease (6.8%), Alzheimer’s disease (4.5%), neuromyelitis optica spectrum disorder (4.5%), Huntington’s disease (2.3%), opioid withdrawal (2.3%), and sedatives (2.3%). Chemically, there are 29 small molecules, 11 biologic monoclonal antibodies (mAbs), 1 antisense oligonucleotide, and 3 combination therapy products. With regard to drug characteristics of these 29 small molecule CNS agents, >70% of these compounds have polar surface area (PSA) values of < 90 Å2, with favorable blood-brain barrier (BBB) penetration profiles; and 19 drugs have logP values ranging from 2 to 5; and 5 drugs had a logP of >5 with more lipophilic profiles. Furthermore, 20 drugs have a basic functionality, with 8 drugs being neutral and 4 being weakly acidic under physiological conditions. Detailed physicochemical properties, PK parameters, and clinical indications, and recommended dosages of these CNS medications will be presented. Conclusion: From 2015-2023, remarkable medicine advances have been made with 400 total new drug approvals from the FDA. Among them, 44 drugs fall within the CNS category, remaining as one of the top 3 drug approval category following oncology and infectious disease. From a medicinal chemistry standpoint, to enable the BBB penetration, most of these CNS approved drugs are lipophilic and basic or neutral as the acidic functionality is not well tolerated due to the negatively charged form under physiological condition. This work serves as a valuable resource and medication information for clinicians and drug discovery researchers.

Browse

Browsing Daniel K. Inouye College of Pharmacy by Issue Date

Results Per Page

Sort Options